Choline fenofibrate (Cholini phenofibras)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Fibrates

Included in the formulation
  • Trilipix®
    capsules inwards 
    Abbot Helskea SAS     France
    • АТХ:

    C.10.A.B.11   Choline fenofibrate

    Pharmacodynamics:

    The prodrug, in the tissues of the body, turns into fenofibroic acid, which increases the activity of the lipoprotein lipase of the vascular wall, increases the catabolism of very low density lipoproteins, and intermediate density lipoproteins, which leads to a decrease in their production.

    Pharmacokinetics:

    After oral administration, an empty stomach is absorbed up to 80% in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 4-5 hours. The connection with plasma proteins is 99%.

    Therapeutic effect develops after the reception. Metabolism in the liver.

    The half-life is 20 hours. Elimination by the kidneys.

    Indications:

    It is used for hyperlipoproteinemia III, IV and V types.

    ICD-10

    IV.E70-E90.E78.0   Pure hypercholesterolemia

    IV.E70-E90.E78.1   Pure hyperglyceridemia

    IV.E70-E90.E78.2   Mixed hyperlipidemia

    IV.E70-E90.E78.3   Hyperchilomicronemia

    Contraindications:

    Severe hepatic and renal insufficiency, cholecystitis, pancreatitis, individual intolerance, children under 18 years of age.

    Carefully:

    Hypothyroidism, chronic alcoholism, history of hereditary muscle diseases, simultaneous use with HMG-CoA reductase inhibitors and oral anticoagulants, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, regardless of the time of ingestion, once, 45-135 mg per day.

    The highest daily dose: 135 mg.

    The highest single dose: 135 mg.

    Side effects:

    Central and peripheral nervous system: headache.

    Hemopoietic system: rarely - anemia, leukocytopenia.

    Respiratory system: interstitial pneumonia.

    The cardiovascular system: rarely - thromboembolism.

    Digestive system: nausea, vomiting, flatulence, diarrhea, cholelithiasis, pancreatitis.

    Musculoskeletal system: myositis, myalgia, rhabdomyolysis.

    Dermatological reactions: a rash, photosensitivity, rarely - alopecia.

    Sense organs: blurred vision.

    Reproductive system: a violation of libido.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic. Hemodialysis is ineffective.

    Interaction:

    At reception of alcohol during treatment by a preparation activity of transaminases raises.

    Antifungal agents, erythromycin, ciclosporin, digoxin - increase the concentration of fenofibroic acid.With simultaneous use, a dose adjustment is required.

    Simultaneous use with inhibitors HMG-CoA-reductase increases the risk of rhabdomyolysis.

    Special instructions:

    It is forbidden to drink alcohol while taking the drug.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up